Chalcogen Or Nitrogen Bonded Directly To The Hetero Ring Patents (Class 514/470)
-
Publication number: 20090082393Abstract: Compounds of formula (I): (A)m·(B)n??(I) wherein A represents an angiotensin-converting enzyme inhibitor compound containing at least one salt-forming basic function, B represents a compound containing at least one salt-forming acid function and at least one NO donor group, m represents the number of acid functions of B that have been converted to a salt and n represents the number of basic functions of A that have been converted to a salt, the bond or bonds between A and B being of the ionic type. Medicinal products containing the same which are useful in treating cardiovascular pathologies.Type: ApplicationFiled: September 17, 2008Publication date: March 26, 2009Applicant: LES LABORATOIRES SERVIERInventors: Guillaume De Nanteuil, Bernard Portevin, Philippe Gloanec, Jean-Gilles Parmentier, Alain Benoist, Tony Verbeuren, Alain Rupin, Christine Courchay, Serge Simonet
-
Publication number: 20090082371Abstract: A method using quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, and 7-Methoxy-5,11,12-trihydroxy-coumestan is administered to a mammal for the treatment and prevention of viral diseases and cancers. The chemical compounds are targeted to inhibit NF-?B transcriptional activity. These treatments for viral diseases, especially for infection caused by HIV, and cancers may be accomplished utilizing quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, 7-Methoxy-5,11,12-trihydroxy-coumestan, and compounds similar to them alone or in combination with prior art other therapy.Type: ApplicationFiled: June 19, 2006Publication date: March 26, 2009Inventor: Zhimin Lu
-
Patent number: 7507763Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: July 21, 2006Date of Patent: March 24, 2009Assignee: Sequoia PharmaceuticalsInventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
-
Publication number: 20090075989Abstract: The present invention relates to non-steroidal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional bleeding and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.Type: ApplicationFiled: December 20, 2007Publication date: March 19, 2009Inventors: Wolfgang Schwede, Carsten Moeller, Anja Schmidt, Ulrike Fuhrmann, Andrea Rotgeri, Thomas Andrew Kirkland, Ralf Wyrwa
-
Publication number: 20090075956Abstract: The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has at least one polymorphism in the endothelial nitric oxide synthase (NOS3) gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt therType: ApplicationFiled: April 7, 2006Publication date: March 19, 2009Applicants: NitroMed, Inc., University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Manuel Worcel, Michael L. Sabolinski, Sang William Tam, Dennis M. McNamara
-
Patent number: 7504428Abstract: The present invention a method of treating anxiety by administering compounds that are active on the GABAB receptor, having formula I: wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification and claims.Type: GrantFiled: May 30, 2008Date of Patent: March 17, 2009Assignee: Hoffman-La Roche Inc.Inventors: Parichehr Malherbe, Raffaello Masciadri, Roger David Norcross, Eric Prinssen
-
Patent number: 7498357Abstract: The present invention provides a novel chalcone compound, its derivative or a salt thereof, each having a suppressive action of NO production or an inhibitory action of aldose reductase. In addition, the present invention provides a medicament, a food, a beverage or a feed having a therapeutic or prophylactic effect for a disease showing sensitivity to the compound, by utilizing the physiological actions of the compound.Type: GrantFiled: December 1, 2004Date of Patent: March 3, 2009Assignee: Takara Bio Inc.Inventors: Hiromu Ohnogi, Katsumi Sugiyama, Tatsuji Enoki, Eiji Kobayashi, Hiroaki Sagawa, Ikunoshin Kato
-
Publication number: 20090047292Abstract: Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositions for suppressing, treating, or preventing graft rejection comprising a substance having an activity to modulate signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 12, 2008Publication date: February 19, 2009Applicant: Japan Tobacco, Inc.Inventors: Seiichi Suzuki, Atsuko Suzuki, Mitsuaki Isobe
-
Publication number: 20090022778Abstract: In a plaster for external use for transdermal absorption in which an adhesive layer is laminated on a plastic backing, the adhesive layer contains a styrene-isoprene-styrene block copolymer (SIS), a tackifying resin and a softener which are essential ingredients, and further contains flurbiprofen blended as an active ingredient. The present plaster for external use is a flurbiprofen containing plaster for external use enabling long-term stable release of contained flurbiprofen, and having excellent stability and very high drug releasing property.Type: ApplicationFiled: February 28, 2005Publication date: January 22, 2009Inventors: Masahiro Yamaji, Takaya Sugawara
-
Publication number: 20090023805Abstract: The present invention relates to the use of mycophenolic acid, a salt or prodrug thereof in immunosuppression, particularly for prevention or treatment of transplant rejection and immune-mediated and/or inflammatory diseases, wherein mycophenolic acid, the salt or the prodrug thereof is administered with an initial intensified dosage regimen.Type: ApplicationFiled: February 12, 2007Publication date: January 22, 2009Inventors: Anne Claire Marrast, Wolfgang Fischer
-
Publication number: 20090004279Abstract: A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.Type: ApplicationFiled: September 10, 2008Publication date: January 1, 2009Inventors: Thomas Hofmann, Alan Bruce Montgomery, Kevin Stapleton, William R. Baker
-
Patent number: 7470724Abstract: The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: April 26, 2004Date of Patent: December 30, 2008Assignee: Gilead Sciences, Inc.Inventors: Carina Cannizzaro, James M. Chen, Xiaowu Chen, Aesop Cho, Lee S. Chong, Manoj Desai, Maria Fardis, Alan X. Huang, Thorsten Kirschberg, Christopher P. Lee, Richard L. Mackman, Peter H. Nelson, Hyung-Jung Pyun, Adrian S. Ray, William J. Watkins, Jennifer R. Zhang, Sundaramoorthi Swaminathan
-
Publication number: 20080319056Abstract: The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.Type: ApplicationFiled: August 26, 2005Publication date: December 25, 2008Inventors: Zhentao Liu, Liying Yang, Hanyu Yang, Yuqing Gao, Dongmin Shen, Wenmin Guo, Xiaolong Feng, Jia Zheng
-
Publication number: 20080312241Abstract: Embodiments of the present invention are related to novel therapeutic drugs, drug combinations, and associated methods for treating or preventing pulmonary disease, including pulmonary hypertension, pulmonary fibrosis, asthma and COPD, and heart failure, together with other pulmonary and cardiovascular diseases and their complications. More particularly, aspects of the present invention are related to the use of cicletanine and ruboxistaurin as monotherapies or in combination with other agents for treatment of disease. Cicletanine may be used as pure (+) or (?) enantiomers or as a racemic or non-racemic mixture of those enantiomers.Type: ApplicationFiled: January 3, 2008Publication date: December 18, 2008Applicant: Gilead Sciences, Inc.Inventors: Glenn V. Cornett, James Page, Wayne A. Jones, Karen Page
-
Publication number: 20080311099Abstract: Methods for treating angina are described. A method for treating angina includes concurrently administering a compound with a therapeutic cardiovascular compound. A combination therapy employs suitable therapeutic cardiovascular compounds, such as a calcium channel blocker, a ?-adrenergic blocker, nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, or a mixture thereof, in combination with a compound such as pyridoxal-5?phosphate, pyridoxic acid, pyridoxal, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. The invention also includes a novel composition comprising at least one compound and nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, calcium channel blockers, ?-adrenergic blockers, or a mixture thereof.Type: ApplicationFiled: September 26, 2005Publication date: December 18, 2008Inventor: Albert Friesen
-
Publication number: 20080305163Abstract: The present invention discloses a novel dosage form of butylphthalide soft capsule and its preparation procedure. Butylphthalide soft capsule is composed of a coating material and a drug-containing oil. The drug-containing oil is basically composed of butylphthalide and diluent—vegetable oil, wherein the weight ratio of butylphthalide to oil ranges from 1:0˜10. The coating material is composed of gelatin, plasticizer and water, wherein the weight ratio of gelatin to plasticizer to water is in the range of 1:0.2˜0.4:0.8˜0.3. The butylphthalide soft capsule described in this invention can mask the strong and specific flavor of butylphthalide, and overcome the difficulties associated with formulating oily active agents into other oral preparations. The disintegration time of the soft capsule complies with the requirement of Pharmacopoeia of P.R. China.Type: ApplicationFiled: August 20, 2008Publication date: December 11, 2008Inventors: Jianqing Li, Min Bai, Wenmin Guo, Surui Chen, Liyun Liu, Guirong Zhou
-
Publication number: 20080305055Abstract: Compounds of the formulae (1), (2) and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of formula (3), wherein Gi is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.Type: ApplicationFiled: October 24, 2005Publication date: December 11, 2008Inventors: Werner Baschong, Oliver Reich, Sebastien Mongiat
-
Publication number: 20080292685Abstract: This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart.Type: ApplicationFiled: December 9, 2005Publication date: November 27, 2008Applicant: BEIJING KANGBEIDE PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTDInventors: Shuming Wang, Li Wang, Xiaoling Fan, Huiyong Xue, Shuang Zhang, Enhong Zhang, Xuying Zhong, Yucheng Lu, Chun Li, Li Song
-
Publication number: 20080293807Abstract: It is intended to provide a skin cosmetic and a wrinkle-reducing agent which are excellent in improving wrinkles caused by photoaging. Namely, a skin cosmetic and a wrinkle-reducing agent containing isosorbide which is represented by the following structural formula (1).Type: ApplicationFiled: April 21, 2006Publication date: November 27, 2008Inventors: Kyoko Miura, Akinori Haratake
-
Publication number: 20080280977Abstract: Provided are processes for the preparation of mycophenolate mofetil and other esters of mycophenolic acid.Type: ApplicationFiled: July 18, 2008Publication date: November 13, 2008Inventors: Sandor Molnar, Csaba Szabo, Tivadar Tamas, Janos Hajko, Claude Singer, Beata Kosztya
-
Publication number: 20080279819Abstract: The present invention provides novel methods and compositions for the treatment and prevention of demyelinating conditions. One demyelinating condition treated by the methods and compositions of the invention is multiple sclerosis. Also treated are symptoms associated with multiple sclerosis.Type: ApplicationFiled: February 15, 2006Publication date: November 13, 2008Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson, David Chernoff
-
Publication number: 20080269322Abstract: The present invention concerns substituted aminophenylsulfonamide compounds, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.Type: ApplicationFiled: November 28, 2006Publication date: October 30, 2008Inventors: Herman Augustinus De Kock, Tim Hugo Maria Jonckers, Stefaan Julien Last, Paul Jozef Gabriel Maria Boonants, Dominique Louis Nestor Ghislain Surleraux, Piet Tom Bert Paul Wigerinck
-
Publication number: 20080268078Abstract: A method for inhibiting nitric oxide and/or prostaglandin E2 synthesis. The method comprises administering a composition to a subject, wherein the composition comprises an effective amount of butylidene phthalide, citronellol, geraniol or combinations thereof, which can be used to reduce or relieve the syndromes of the inflammation.Type: ApplicationFiled: October 3, 2007Publication date: October 30, 2008Inventors: Yu-Wen Su, Meng-Hwan Lee
-
Publication number: 20080260861Abstract: Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed.Type: ApplicationFiled: April 7, 2005Publication date: October 23, 2008Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Jeroeng Hagendoorn, Dai Fukumura, Timothy P. Padera, Rakesh K. Jain
-
Publication number: 20080262086Abstract: Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.Type: ApplicationFiled: April 18, 2008Publication date: October 23, 2008Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20080255061Abstract: Disclosed a class of phthalide derivatives and the use of which to manufacture the sensitizer or reverser of the antineoplastic agent.Type: ApplicationFiled: September 30, 2005Publication date: October 16, 2008Inventors: Fei Chen, Tao Wang
-
Publication number: 20080242713Abstract: This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1-R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating autoimmune diseases. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: March 27, 2008Publication date: October 2, 2008Inventors: William Guilford, Werner Skuballa, Daryl H. Faulds, Monica Kochanny, Wheeseong Lee, Bernd Raduchel
-
Publication number: 20080242714Abstract: This invention is directed to compounds of formula (I): where A, B, D, E, m, and R1-R5 are as described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, clathrates, or prodrugs thereof, which compounds are useful in treating respiratory diseases associated with influenza A viruses, such as for example H5N1 and its mutations. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: March 27, 2008Publication date: October 2, 2008Applicant: Bayer Schering Pharma AktiengesellschaftInventors: William Guilford, Werner Skuballa, Daryl H. Faulds, Monica Kochanny, Wheeseong Lee, Bernd Raduchel
-
Publication number: 20080227856Abstract: The present invention relates to novel compositions, which provide an indicator for location and/or concentration of the composition during application. Following application, the indicator is no longer visible to the user. In one embodiment, the indicator is a compound that is visible at a first pH and not visible at a second pH. In another embodiment, the indicator is a photosensitive or light unstable dye, where the dye is visible for a temporary period following exposure to light.Type: ApplicationFiled: April 28, 2008Publication date: September 18, 2008Inventor: Richard J. Melker
-
Publication number: 20080226758Abstract: The present invention relates to methods, compositions and their constituents for inhibiting 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), using processed Morinda citrifolia L. plant products.Type: ApplicationFiled: November 27, 2007Publication date: September 18, 2008Inventors: Shixin Deng, Brett West, Afa Palu, Chen Xing Su, Bing-Nan Zhou, Claude Jarakae Jensen
-
Publication number: 20080214648Abstract: The present invention provides new prodrugs which are conjugates of a therapeutic compound and a peptide wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV).Type: ApplicationFiled: May 10, 2004Publication date: September 4, 2008Inventors: Herman Augustinus De Kock, Piet Tom Bert Paul Wigerinck, Jan Balzarini
-
Patent number: 7419967Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods For inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.Type: GrantFiled: August 25, 2005Date of Patent: September 2, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Michael R Hale, Clarence W Andrews, III, Eric S Furfine, Ronald G Sherrill, Andrew Spaltenstein, Gregory T Lowen
-
Patent number: 7420001Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.Type: GrantFiled: December 1, 2004Date of Patent: September 2, 2008Assignee: WyethInventors: Jeremy Ian Levin, Thomas Saltmarsh Rush, III, Frank Lovering, Yonghan Hu, Jianchang Li, Wei Li, Jun Jun Wu, Rajeev Hotchandani, Jason Shaoyun Xiang, Xuemei Du, Derek Cecil Cole, Steve Yikkai Tam
-
Publication number: 20080207713Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: June 8, 2006Publication date: August 28, 2008Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Publication number: 20080206322Abstract: The present invention relates to a novel composition, e.g. of mycophenolic acid, a salt or a prodrug thereof, in a modified release form.Type: ApplicationFiled: August 29, 2005Publication date: August 28, 2008Applicant: NOVARTIS AGInventors: Dieter Becker, Jutta Beyer, Janez Kerc, Andrea Kramer, Nicoletta Loggia, Chirstian-Peter Luftensteiner, Jorg Ogorka
-
Publication number: 20080193499Abstract: Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.Type: ApplicationFiled: June 27, 2005Publication date: August 14, 2008Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jun Liu, Curtis Chong, David J. Sullivan
-
Publication number: 20080193385Abstract: The present invention relates to compositions and methods for alleviating the painful symptoms due to neuropathy. Specifically, the method involves administering to a patient a composition comprising a nitric oxide donor that may be applied topically on the legs or arms to alleviate the negative effects due to neuropathy.Type: ApplicationFiled: October 31, 2007Publication date: August 14, 2008Inventor: Todd Maibach
-
Publication number: 20080161389Abstract: The present invention relates to a method of treating an ophthalmological disease mediated by ocular hypertension or an intestinal disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a tautomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof.Type: ApplicationFiled: March 1, 2007Publication date: July 3, 2008Applicant: LACER, S.A.Inventors: Jose Repolles Moliner, Francisco Pubill Coy, Marisabel Mourelle Mancini
-
Patent number: 7393825Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to 1/20) of those known to induce vasodilation in “normal” circulations.Type: GrantFiled: June 11, 2003Date of Patent: July 1, 2008Assignee: Strakan International LimitedInventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
-
Publication number: 20080153873Abstract: The present invention is directed to dihydrobenzofuranyl derivatives of formula I: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.Type: ApplicationFiled: December 12, 2007Publication date: June 26, 2008Applicant: WyethInventors: Puwen Zhang, Joseph Peter Sabatucci, Eugene Anthony Terefenko, Eugene John Trybulski
-
Publication number: 20080139646Abstract: The present invention is directed to a mixture of at least two different alkylated phenolphthalein ester compounds. Specifically, the present invention is directed to a mixture of at least two different compounds of formula I: wherein R1 represents a straight chain alkyl group having 1 to 11 carbon atoms; R2 represents a hydrogen atom or a group of the formula C(O)R4 where R4 is a hydrogen atom or a straight chain alkyl group having 1 to 11 carbon atoms; X2-X5 independently represent hydrogen; X6-X13 is same or different, and represents hydrogen or a straight or branched chain alkyl group having 1 to 12 carbon atoms. It further relates to a marker composition containing said mixtures dissolved in a solvent.Type: ApplicationFiled: December 7, 2007Publication date: June 12, 2008Inventors: Justin J. Frederico, Bharat Desai, Michael J. Smith, Michael P. Hinton
-
Patent number: 7378441Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: May 9, 2005Date of Patent: May 27, 2008Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Andrey Topin, Greg Delahanty, Gnana Ravi Rajendran
-
Patent number: 7371774Abstract: The invention relates to compounds of the general formula (I) below: in which R1, R2, R3, R4, R5, R6 and X are as defined in claim 1. These compounds can be used in the treatment of pathologies associated with insulin resistance syndrome.Type: GrantFiled: November 8, 2004Date of Patent: May 13, 2008Assignee: Merck Patent GmbHInventors: Gérard Moinet, Caroline Leriche, Micheline Kergoat
-
Patent number: 7351735Abstract: This invention relates to novel benzofuran and benzothiophene derivatives of the general table formula and their use for the treatment of hyper-proliferative disordersType: GrantFiled: February 21, 2003Date of Patent: April 1, 2008Assignee: Bayer Pharmaceuticals CorporationInventors: Chengzhi Zhang, Michael Burke, Zhi Chen, Jacques Dumas, Dongping Fan, Jianmei Fan, Holia Hatoum-Mokdad, Benjamin D. Jones, Gaetan Ladouceur, Wendy Lee, Barton Phillips
-
Patent number: 7332522Abstract: A liver function protecting or improving agent which comprises a compound represented by the formula (I) {in the formula (I), R1, R2, R3, R4, R5, R6, R7, R8 and R9 may be the same or different, and represent hydrogen, halogen, hydroxy, alkoxy or alkyl; and RA represents the formula (II) [in the formula (II), R10 and R11 may be the same or different, and represent hydrogen or halogen, or R10 and R11 together represent a binding] or the formula (III) [in the formula (III), R12 represents hydrogen, halogen, hydroxy, alkoxy, cyano or alkyl, R13 and R14 may be the same or different, and represent hydrogen or halogen, or R13 and R14 together represent a binding]} or a glycoside thereof or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 28, 2002Date of Patent: February 19, 2008Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Yasushi Sakai, Shun Kayahashi, Erika Hashizume, Ryusuke Nakagiri
-
Publication number: 20080033019Abstract: A patient with dyslipidemia is treated with a cholesterol blood level lowering effective amount of a non-statin cholesterol lowering agent and an amount of nitric oxide (NO) donating compound effective to mediate increase in nitric oxide bioactivity in blood.Type: ApplicationFiled: June 19, 2007Publication date: February 7, 2008Applicant: Duke UniversityInventor: Jonathan S. Stamler
-
Publication number: 20080027114Abstract: The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other acaricidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarids.Type: ApplicationFiled: October 10, 2004Publication date: January 31, 2008Applicant: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: Christian Funke, Thomas Bretscheneider, Reiner Fischer, Rudiger Fischer, Heike Hungenberg, Wolfram Andersch, Wolfgang Thielert, Anton Kraus
-
Publication number: 20080025972Abstract: Sex steroid potentiated disorders including, prostate cancer and breast cancer, in a patient in need of treatment thereof, are treated with an amount of nitric oxide donating compound and/or nitrosoglutathione reductase inhibitor and/or cysteine binder different from that provided by nitric oxide donating compound effective to inhibit activation of steroid receptor. Variations include using only nitric oxide donating agent as treating agent; using only nitrosoglutathione reductase inhibitors as treating agent, using nitric oxide donating agent plus nitrosoglutathione reductase inhibiting agent; for prostate cancer treatment using prostate cancer drug modified to contain nitric oxide donating moiety or FDA approved nitric oxide donating agent and FDA approved prostate cancer treating agent. Also disclosed is an assay for assessing mutagenic potential of prostate cancer in a patient.Type: ApplicationFiled: May 21, 2007Publication date: January 31, 2008Applicant: Duke UniversityInventors: Yehia Daaka, Jonathan S. Stamler
-
Publication number: 20080020034Abstract: The present invention discloses a novel dosage form of butylphthalide soft capsule and its preparation procedure. Butylphthalide soft capsule is composed of a coating material and a drug-containing oil. The drug-containing oil is basically composed of butylphthalide and diluent—vegetable oil, wherein the weight ratio of butylphthalide to oil ranges from 1:0-10. The coating material is composed of gelatin, plasticizer and water, wherein the weight ratio of gelatin to plasticizer to water is in the range of 1:0.2{tilde over ( )}0.4:0.8{tilde over ( )}0.3. The butylphthalide soft capsule described in this invention can mask the strong and specific flavor of butylphthalide, and overcome the difficulties associated with formulating oily active agents into other oral preparations. The disintegration time of the soft capsule complies with the requirement of Pharmacopoeia of P.R. China.Type: ApplicationFiled: December 3, 2004Publication date: January 24, 2008Inventors: Jianqing Li, Min Bai, Wenmin Guo, Surui Chen, Liyun Liu, Guirong Zhou
-
Patent number: 7273886Abstract: Compounds of Formula I are useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein and have improved pharmacokinetic properties. These compounds may be used in methods of preventing and/or treating clotting disorders.Type: GrantFiled: May 19, 2004Date of Patent: September 25, 2007Assignee: Genentech, Inc.Inventors: Alan G. Olivero, Daniel P. Sutherlin